2025 is a big year for RoukenBio!
We're proud to announce we have new data using our trademark dual inducible cell line system — IndEx-2. ?
The technology can help drug developers:?
In the words of Dr Timothy London, our Scientific Director of Molecular Biology, IndEx-2 "allows you to build a more complete picture of the activity profile of candidate therapeutics.” Read the latest data from our Cell Engineering team.?
Introducing our in vitro models ??
In vitro pre-clinical models are crucial to de-risk drug development, inform decision making, and reduce reliance on animal testing. Our CSO Dr Agapitos Patakas introduces the in vitro models driving drug development in our new blog.?
2025 conferences ??
The 2025 conference season is in full swing! Our experts will be showcasing our bioassay services across drug development at the following events:
Attending a conference? Pre-book a meeting with us.
Share your thoughts and leave us feedback! ??
Is there anything you would you like to see in our newsletter in the future? Please email your thoughts and suggestions to [email protected].
Best wishes,
The RoukenBio Team
Facilitating scientist to scientist support outsourcing innovative immunological assays. Making it simpler for our customers to succeed.
1 个月So many new aspects to help our customers answer pre-clinical questions RoukenBio! Excited to see all they ways we use them in 2025 ??